259 related articles for article (PubMed ID: 16632640)
1. Antitumor activity of sphingosine kinase inhibitors.
French KJ; Upson JJ; Keller SN; Zhuang Y; Yun JK; Smith CD
J Pharmacol Exp Ther; 2006 Aug; 318(2):596-603. PubMed ID: 16632640
[TBL] [Abstract][Full Text] [Related]
2. Discovery and evaluation of inhibitors of human sphingosine kinase.
French KJ; Schrecengost RS; Lee BD; Zhuang Y; Smith SN; Eberly JL; Yun JK; Smith CD
Cancer Res; 2003 Sep; 63(18):5962-9. PubMed ID: 14522923
[TBL] [Abstract][Full Text] [Related]
3. Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids.
Yan G; Chen S; You B; Sun J
Cardiovasc Res; 2008 May; 78(2):308-14. PubMed ID: 18192241
[TBL] [Abstract][Full Text] [Related]
4. Targeting sphingosine kinase 1 in carcinoma cells decreases proliferation and survival by compromising PKC activity and cytokinesis.
Kotelevets N; Fabbro D; Huwiler A; Zangemeister-Wittke U
PLoS One; 2012; 7(6):e39209. PubMed ID: 22761740
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine kinase as an oncogene: autocrine sphingosine 1-phosphate modulates ML-1 thyroid carcinoma cell migration by a mechanism dependent on protein kinase C-alpha and ERK1/2.
Bergelin N; Blom T; Heikkilä J; Löf C; Alam C; Balthasar S; Slotte JP; Hinkkanen A; Törnquist K
Endocrinology; 2009 May; 150(5):2055-63. PubMed ID: 19116345
[TBL] [Abstract][Full Text] [Related]
6. [Sphingosine kinase 1 and tumor].
Zhang CX; He HW; Shao RG
Yao Xue Xue Bao; 2013 Jul; 48(7):971-8. PubMed ID: 24133963
[TBL] [Abstract][Full Text] [Related]
7. A novel mode of action of the putative sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (SKI II): induction of lysosomal sphingosine kinase 1 degradation.
Ren S; Xin C; Pfeilschifter J; Huwiler A
Cell Physiol Biochem; 2010; 26(1):97-104. PubMed ID: 20502009
[TBL] [Abstract][Full Text] [Related]
8. Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase.
Pitson SM; Moretti PA; Zebol JR; Xia P; Gamble JR; Vadas MA; D'Andrea RJ; Wattenberg BW
J Biol Chem; 2000 Oct; 275(43):33945-50. PubMed ID: 10944534
[TBL] [Abstract][Full Text] [Related]
9. From Sphingosine Kinase to Dihydroceramide Desaturase: A Structure-Activity Relationship (SAR) Study of the Enzyme Inhibitory and Anticancer Activity of 4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II).
Aurelio L; Scullino CV; Pitman MR; Sexton A; Oliver V; Davies L; Rebello RJ; Furic L; Creek DJ; Pitson SM; Flynn BL
J Med Chem; 2016 Feb; 59(3):965-84. PubMed ID: 26780304
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine kinase 1 in cancer.
Heffernan-Stroud LA; Obeid LM
Adv Cancer Res; 2013; 117():201-35. PubMed ID: 23290781
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors.
Bassi R; Anelli V; Giussani P; Tettamanti G; Viani P; Riboni L
Glia; 2006 Apr; 53(6):621-30. PubMed ID: 16470810
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine kinase activation regulates hepatocyte growth factor induced migration of endothelial cells.
Duan HF; Wu CT; Lu Y; Wang H; Liu HJ; Zhang QW; Jia XX; Lu ZZ; Wang LS
Exp Cell Res; 2004 Aug; 298(2):593-601. PubMed ID: 15265705
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine kinase 1 as an anticancer therapeutic target.
Gao Y; Gao F; Chen K; Tian ML; Zhao DL
Drug Des Devel Ther; 2015; 9():3239-45. PubMed ID: 26150697
[TBL] [Abstract][Full Text] [Related]
14. ATP-binding cassette ABCC1 is involved in the release of sphingosine 1-phosphate from rat uterine leiomyoma ELT3 cells and late pregnant rat myometrium.
Tanfin Z; Serrano-Sanchez M; Leiber D
Cell Signal; 2011 Dec; 23(12):1997-2004. PubMed ID: 21803151
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine kinase and sphingosine-1-phosphate regulate epithelial cell architecture by the modulation of de novo sphingolipid synthesis.
Santacreu BJ; Pescio LG; Romero DJ; Corradi GR; Sterin-Speziale N; Favale NO
PLoS One; 2019; 14(3):e0213917. PubMed ID: 30897151
[TBL] [Abstract][Full Text] [Related]
16. PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA).
Johnson KR; Becker KP; Facchinetti MM; Hannun YA; Obeid LM
J Biol Chem; 2002 Sep; 277(38):35257-62. PubMed ID: 12124383
[TBL] [Abstract][Full Text] [Related]
17. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells.
Nagaoka Y; Otsuki K; Fujita T; Uesato S
Biol Pharm Bull; 2008 Jun; 31(6):1177-81. PubMed ID: 18520051
[TBL] [Abstract][Full Text] [Related]
18. Targeting sphingosine kinase-1 to inhibit melanoma.
Madhunapantula SV; Hengst J; Gowda R; Fox TE; Yun JK; Robertson GP
Pigment Cell Melanoma Res; 2012 Mar; 25(2):259-74. PubMed ID: 22236408
[TBL] [Abstract][Full Text] [Related]
19. Increased sphingosine 1-phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy.
Yaghobian D; Don AS; Yaghobian S; Chen X; Pollock CA; Saad S
Clin Exp Pharmacol Physiol; 2016 Jan; 43(1):56-66. PubMed ID: 26414003
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.
LeBlanc FR; Liu X; Hengst J; Fox T; Calvert V; Petricoin EF; Yun J; Feith DJ; Loughran TP
Cancer Biol Ther; 2015; 16(12):1830-40. PubMed ID: 26252351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
